Past Issue

Volume 9, Supplement 1, Summer 2015 (Presented at 16th Congress on Reproductive Biomedicine and 10th Royan Nursing and Midwifery Seminar) Pages: 81-82

P-92: Compare The Efficacy of Two Protocols of Ovarian Stimulation Using Recombinant FSH Plus Recombinant LH versus Recombinant LH Alone in Hypogonadotropic Hypogonadal Women Undergoing In Vitro Fertilization/ Intracytoplasmic Sperm Injection (IVF/ICSI)

To compare the efficacy of recombinant follicle- stimulating hormone (rFSH) plus recombinant luteinizing hormone (rLH) versus LH alone during the late follicular phase for ovarian stimulation in hypogonadotropic hypogonadal (HH) women undergoing in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI).
Materials and methods
In this prospective, single-blind, randomized clinical trial, 51 HH infertile women undergoing IVF/ICSI were enrolled and received 150 IU/d rFSH (with the possibility of dose adjustment) and 75 IU/d rLH for ovarian stimulation. When at least one follicle reached 14 mm in diameter, treatment with rLH alone or rFSH plus rLH were randomly assigned. The main outcome measures were the number of mature follicles, the endometrial thickness on the day of human chorionic gonadotropin (hCG) administration, the number of oocytes retrieved, implantation rate and clinical pregnancy rate.
The number of mature follicles, the endometrial thickness on the day of hCG administration and the number of oocytes retrieved were similar in the two groups. The implantation and clinical pregnancy rates were higher in group rLH as compared with group rFSH/ rLH, but the differences were not significant (implantation rate: 34.7% vs. 20.0% with P=0.112; clinical pregnancy rate: 50.0% vs. 38.9% with P=0.492).
The ovarian stimulation by rLH alone versus rFSH/rLH during the late follicular phase showed better effect on final outcomes of IVF/ICSI in HH women. Therefore, the use of rLH alone during the late follicular phase can be effective in treatment of HH women undergoing IVF/ICSI cycles.